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Summary 
The ultraviolet circular dichroism (CD) spectra of commercial 
low-molecular-weight heparins, heparinoids and other anti-
coagulant preparations have been recorded between 180 and 
260 nm. Principal component analysis of the spectra allowed 
their differentiation into a number of groups related to the 
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means of their production reflecting the structural changes in-
troduced by each process. The findings suggest that CD provides 
a complementary technique for the rapid analysis of heparin 
preparations. 
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Introduction 
The linear anionic polysaccharide heparin, which is widely em-
ployed as an anticoagulant is composed of a major disaccharide 
repeat unit of 1,4 O-linked α-L-iduronic acid and α-D-glucosa-
mine, in which the predominant substitution pattern is 2-O-sul-
fation of the iduronate residues and N- and 6-O-sulfation of the 
glucosamine residues. A number of other substitutions are possi-
ble, including N-acetylation and 3-O-sulfation in glucosamine 
and both non-sulfated iduronate and β-D-glucuronate can occur, 
providing considerable sequence heterogeneity (1). Recently, the 
issue of heparin quality control and monitoring has attracted at-
tention following the observation of serious side-effects thought 
to have arisen from samples of full-length heparin tainted with 
over-sulfated chondroitin sulfate (2, 3). This has also been shown 
to be a problem affecting low-molecular-weight heparins 
(LMWHs). Indeed, alkaline catalysed β-elimination and H2O2 
oxidative treatments, that are widely used to depolymerise hepa-
rin, also degraded the over-sulfated chondroitin sulfate contami-
nant (4) effectively concealing it in LMWH preparations.  
Pharmaceutically, heparin acts by binding antithrombin III 
(AT), increasing its rate of factor Xa inactivitation by two to three 
orders of magnitude. The [Heparin:AT] complex inhibits several 
procoagulant serine proteases in addition to factor Xa, including 
factors IIa (thrombin), IXa, XIa and XIIa. Among other factors, 
the catalytic activity of heparin is dependent on both chain length 
and the presence of “AGAIA” pentasaccharide sequences based 
on [--4) α-D-GlcNS,6S (1–4) β-D-GlcA (1–4) 
α-D-GlcNS,3S,6S (1–4) α-L-IdoA2S (1–4) α-D-GlcNS,6S 
(1--], a family of high-affinity binding sequences for AT that 
causes a conformational change resulting in increased inhibition 
of factor Xa. Approximately 30% of full-length heparin chains 
contain this high affinity sequence, but only 15–25% of LMWH 
chains. This sequence also forms the basis of the synthetic anti-
coagulant drug fondaparinux sodium (FS) (5). Effective cataly-
sis of AT-mediated inhibition of factor IIa (thrombin) requires 
the presence of the high-affinity pentasaccharide sequence, but 
also that the saccharide be at least 18 (6) residues in length, be-
cause it must bind and bridge both AT and factor IIa. LWMHs 
have a molecular weight typically between 4–6.5 kDa (their 
chain lengths vary from approximately 8 to 14 residues), while 
retaining considerable anti-Xa activity, but exhibiting attenuated 
anti-IIa activity, thereby providing the important ability to affect 
these two proteins either selectively or jointly. In recent years, 
unfractionated heparin has been replaced in many applications 
by LMHWs and heparinoids. 
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LMWHs are produced by the depolymerisation of heparin 
chains. This can be achieved by a number of methods, including 
deaminative degradation using nitrous acid (7), scission by isoa-
myl nitrate (8), β-elimination under basic conditions, lysis by 
bacterially derived eliminase enzymes (9) and oxidative depoly-
merisation, for example, with hydrogen peroxide (10). These 
treatments can result in structural modifications in addition to 
depolymeristion, for example the introduction of anhydroman-
nose terminal reducing end residues during nitrous acid-based 
cleavage and introduction of a characteristic 4,5 unsaturated 
non-reducing end uronic acid terminal residue following either 
enzymatic cleavage or β-elimination. 
Circular dichorism (CD; more properly termed electronic 
circular dichroism) is a powerful spectroscopic technique that is 
widely used to investigate protein secondary structure, but it has 
also been employed to probe the structure of heparin and other 
glycosaminoglycans (GAGs) (11, 12). The C-5 epimers of hex-
uronic acid (D-GlcA and L-IdoA) have significant CD spectra of 
opposite sign (13) and these residues are also major chiral chro-
mophores in GAGs, including heparin. Heparin contains a 
relatively lower proportion (which is variable, being-around 20 
% in porcine intestinal mucosal heparin) of N-acetyl groups than 
other GAGs. The CD spectra of heparin, related GAGs and 
chemically modified derivatives have a number of prominant 
features; a negative spectral feature at ~210 nm arising from 
n→π* transitions in carboxylate groups (13), a positive feature 
at ~190 nm containing transitions attributed to oxygen [glyco-
sidic linkage, ring and hydroxyl] (14) and N-sulfate groups (15) 
as well as transitions [n→π* and π→π*] in the N-acetyl (amide) 
group giving rise to spectral features at ~210 and ~190 nm (16). 
However, the details of the CD spectra of GAGs have been found 
to be very sensitive to changes in the environment of the uronic 
acids in particular. These changes can be induced by altered sub-
stitution patterns or the binding of particular cations (11). 
 While the need to provide improved methods for the quality 
control and monitoring of heparin has been highlighted by recent 
concerns over contaminants, the practical challenge of easily dif-
ferentiating between heparin originating from distinct origins, 
via particular methods of production, or comparing batch to 
batch variation for quality control purposes using one relatively 
simple technique, is formidable. This can be tackled using nu-
clear magnetic resonance (NMR) spectroscopy (17, 18), but its 
Figure 1: CD spectra, loading plot and heirarchical cluster 
analysis of LMWHs and heparinoids. A) CD spectra of individual 
samples of LMWHs and heparinoids. B) Loading plot derived from PCA 
of mean-centred CD spectra of LMWHs and heparinoids. C) Heirarchi-
cal cluster analysis performed on the load plot derived from PCA of 
mean-centred CD spectra of LMWHs and heparinoids. The methods 
employed to prepare the samples were as follows: Nitrous acid degrada-
tion; dalteparin sodium (DNS) and reviparin sodium (RS). Synthesis; fon-
daparinux sodium (FS). Cleavage with isoamyl nitrite; certaparin sodium 
(CNS). Oxidative depolymerisation with hydrogen peroxide; ardeparin 
sodium (AS) and sulfodexide (S); β-elimination with base; enoxaparin so-
dium (ES) and lyase enzyme degradation; tinzaparin sodium (TS). Note 
that danaparoid sodium (DPS) and sulodexide are both heparinoids con-
taining, in the case of DPS, predominantly low-molecular-weight HS with 
DS and CS and in the case of sulodexide, predominantly LMWH with 
DS.  
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relative complexity and expense still leaves room for additional 
and complementary methods. It has also been shown recently 
that CD is able to differentiate GAGs effectively (12) and does so 
on the basis of the distinct physical processes that are comple-
mentary to NMR. 
 The analysis of the CD spectra of GAGs has been achieved 
here through the application of multivariate analysis, a powerful 
statistical tool, which has been used to extract relationships from 
many forms of spectra and numerical data relating to GAGs (11, 
12, 19). The application of multivariate analysis permits spectra 
to be systematically compared and their similarities and differ-
ences to be evaluated (12, 20, 21).  
 We demonstrate that CD can be used to distinguish LMWHs 
in terms of the means employed in their production and also dif-
ferentiate these from heparinoids containing other GAGs. Fur-
thermore, the ability of CD to differentiate between these and 
other GAGs, including dermatan and chondroitin sulfate is 
shown. 
Methods and materials 
SRCD 
SRCD spectra were recorded on beamline 12.1 at Daresbury 
Laboratory, a purpose-built synchrotron radiation circular dich-
roism (SRCD) facility, using a quartz sample cell (Hellma; 0.02 
cm path length, 1 nm resolution), from 260 to 180 nm. Spectra 
were recorded (at 10 mg/ml) relative to (+)-10-camphorsulfonic 
acid (1.0 mg/ml).  
Factor analysis 
Factor analysis is used to uncover the latent structure (dimen-
sionality) of a dataset and reduces a large number of variables to 
a smaller number of factors encapsulating the crucial informa-
tion, while eliminating the noise. Consider a dataset xij (cases i 
and variables j, (i=1,…,n;j=1,…,k)), factor analysis allows xij to 
be expressed as a combination of r factors, ξ. 
xij=λj1ξi1+λj2ξi2+,…,+λjrξir+σij. The λ terms correspond to the 
factor loadings to be estimated and σij is the measurement error in 
xij, or is the part of xij that is not accounted for by the r underlying 
factors. In matrix notation, this representation can be expanded 
to; X=ΠΓ’+Δ, X (n by k matrix) – the observed cases, Π (n by r 
matrix) – the scores on the underlying factors, Γ’ (r by k matrix) 
– the transpose of the factor loadings, and Δ (n by k matrix) – the 
measurement errors. The most common form of FA is principal 
component analysis (PCA). PCA performs the optimum co-ordi-
nate rotation to align the axes so that the variance within the data 
is maximised, therefore transforming a set of correlated variables 
into a set of uncorrelated variables. The most common form of ro-
tation is the varimax rotation, which seeks to minimise the com-
plexity of the components by maximising the larger loadings and 
minimising the smaller loadings within each factor/component. 
These uncorrelated variables are linear combinations of the orig-
inal variables and the linear combination which extracts the maxi-
mum variance from the variables is the first principal component. 
Once this is found it is removed and another set of linear combi-
nations, which explains the maximum proportion of the remain-
ing variance is found, providing the second principal component. 
This continues until all the variance of the dataset can be ex-
plained. There can be as many components as variables (22). 
Multivariate analysis  
Multivariate analysis was performed using SPSS 15.0 (SPSS UK 
Ltd., Woking, UK), with prior mean-centering. Factor analysis 
was performed, with components extracted by PCA with a cor-
relation matrix. The components were then rotated using the 
varimax method. Cluster analysis was performed using Minitab 
Figure 2: Multivariate 
analysis of CD spectra of 
LMWHs and other GAGs. 
A) CD spectra of LMWHs, 
heparinoids, CS and DS. 
B) Load plot derived from 
PCA of mean-centred CD 
spectra of LMWHs, hepari-
noids, CS and DS spectra. 
C) Cluster analysis performed 
on the load plot. Additional 
GAGs included in this analysis 
were all high-molecular-
weight samples; heparin from 
porcine intestinal mucosa, CS 
from bovine trachea, DS and 
chondroitin sulfate from por-
cine trachea. 
Rudd, Skidmore, et al. Circular dichroism of LMWHs
877
(Minitab Ltd., Coventry, UK) with single linkage. Euclidean dis-
tances were measured and clusters were determined by 80% 
similarity. 
Definitions 
Components represent the underlying dimensions that summa-
rise or account for the original set of observed data. Component 
loadings are the correlation coefficients between the variables 
(rows) and factors (columns), the squared factor loadings indi-
cate the percentage of the variance in the original variable that is 
explained by a factor. Component scores are a composite 
measure created for each observation on each factor extracted in 
the factor analysis. 
Results 
1. Circular dichroism differentiates LMWH samples 
in terms of their method of production and can 
distinguish LMWHs and heparinoids 
The heparin CD spectra were of the expected form, with a posi-
tive peak at approximately 190 nm and a negative peak at 210 
nm. For eight of the spectra the positive peak arose at 192 nm. 
These eight were split into two groups, the first consisted of dal-
teparin sodium (DNS), certaparin sodium (CS), reviparin so-
dium (RS) and tinzaparin sodium (TS), and the second contained 
danaparoid sodium (DPS), ardeparin sodium (AS), enoxaparin 
sodium (ES) and sulodexide. The final sample, FS, was distinct 
from the other eight samples in that its positive band arose at 195 
nm. The positive band at 190 nm can be attributed to electronic 
transitions in oxygen atoms (ring, glycosidic linkage and hydro-
xyl). Regarding the negative band at 210 nm, the spectra fell into 
three groups, the first contained FS, again being distinct, the sec-
ond contained the non-CS/DS containing samples, while the 
third contained the heparanoids; DS and sulodexide containing 
CS/DS. The increased magnitude of the peak at 210 nm for the 
heparanoids can be explained by the presence of CS, which has 
a strong negative feature at 210 nm (Fig. 2A), arising from the 
N-acetyl groups, which became more prominant following the 
addition of uniformally N-acetylated CS to the heparin sample, 
and which contained a low proportion of N-acetyl groups. The 
most distinct feature was a negative band at 230 nm, found only 
in ES and TS, which were depolymerised by β-elimination and 
lyase enzyme digestion, respectively, both of which result in the 
introduction of a 4,5 double bond (C=C) into the non-reducing 
end terminal uronate residue. With the exception of FS, which is 
unique in being the only sample to comprise a single chemical 
entity, the AGAIA pentasaccharide specific for ATIII; DS, CS, 
RS and AS are derived using methods which cut the heparin 
chain without introducing additional chromophores and com-
prise another distinct group.  
The three components (Fig. 1B) used to differentiate the 
LMWHs and heparanoids by PCA explained 96.3% of the vari-
ance with the mean-centred data set; component 1 differentiated 
between the heparanoids and the LMWHs depolymerised by 
β-elimination or lyase enzyme digestion. The component score 
plot for component 1 showed that the spectral features which dif-
ferentiated the two groups of samples were the strengthened 
minima at 210 nm for the heparanoids and the minima at 230 nm, 
which were specific to the LMWHs depolymerised by β-elimin-
ation or lyase enzyme digestion. Component 2 differentiated FS 
from the rest of the LMWHs and heparanoids, the score plot for 
component 2 indicated that the shift in the maxima for FS from 
192 to 195 nm and smaller minima at 210 nm were the differenti-
ating features. Component 3 differentiated between samples de-
polymerised by nitrous acid and isoamyl nitrite and to a lesser ex-
tent, those depolymerised by oxidative cleavage, from hepara-
noids, LMWHs depolymerised by β-elimination or lyase 
enzyme digestion, and FS. The component score plot for com-
ponent 3 indicated that the differentiating spectral features were 
the maxima at 192 nm (component plots and component score 
plots not shown).  
2. CD can also differentiate between LMWHs, 
heparinoids and other GAGs 
Spectra of two other naturally occurring glycosaminoglycans, 
CS and DS, were also analysed by PCA. The spectra and their 
analysis, shown in Figure 2, demonstrated that there was a clear 
contrast between the heparin-like spectra of the LMWHs and he-
parinoids and those of pure DS and CS. CD readily differentiated 
the pharmaceuticals from the full-length glycosaminoglycans, 
CS and DS. The structural modifications that occured due to de-
polymerisation of full-length heparin provided the means to 
monitor the identity and purity of LMWHs by circular dichroism 
spectroscopy and PCA. 
Conclusion and discussion 
CD spectroscopy between 180 and 260 nm is a useful additional 
tool to distinguish LMWH samples from heparinoids and both of 
these from other full-length GAGs. Furthermore, within the 
LMWH samples, CD can differentiate between samples that 
have been produced using particular depolymerisation tech-
niques. The basis of the ability of CD to differentiate between 
these samples resides in its sensitivity to the introduction of 
chromophores such as additional N-acetyl groups, in the case of 
heparinoids, or the addition of these groups to even higher levels 
in the cases of CS and DS, or modified uronic acid residues con-
taining double bonds, in the case of the products of enzymatic 
cleavage or β-elimination.  
 The ability of CD to achieve this lends itself to future appli-
cations in the quality control and monitoring of pharmaceutical 
grade heparin preparations. CD provides an additional and 
highly complementary method to other existing monitoring pro-
cedures, in that it detects particular physical parameters which 
are distinct to those detected by other techniques. CD is also 
highly sensitive to the presence of other chiral entities such as 
proteins and peptides, which are of obvious relevance to the 
quality control of heparin preparations. 
 The measurements made here were all recorded on a pur-
pose-built synchrotron CD beamline (SRS, Daresbury, UK) but, 
with recent improvements in commercial CD instrumentation, 
could be obtained readily using standard laboratory CD instru-
ments. The application of principal component analysis to the 
CD spectra permitted a systematic and objective comparison of 
the spectra to be made and lends itself to automation as well as 
the assembly of libraries of spectra.  
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